Sigma-Aldrich, Scripps Research Institute Partner on Reagents Development, Commercialization | GenomeWeb

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said it is partnering with the Scripps Research Institute to develop and commercialize new reagents.

The deal, the company said, will "fund research and provide immediate day-of-publication access to [Scripps] researchers' discoveries for the synthesis and analysis of potential drugs," and, further, could "eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.